The impact of chronic renal insufficiency on vascular surgery patient outcomes  by Nathan, Derek P. & Tang, Gale L.
Available online at www.sciencedirect.comwww.elsevier.com/locate/semvascsurg
S E M I N A R S I N V A S C U L A R S U R G E R Y 2 7 ( 2 0 1 4 ) 1 6 2 – 1 6 9http://
0895-7
(http://
nCor
E-mThe impact of chronic renal insufﬁciency on
vascular surgery patient outcomes
Derek P. Nathana, and Gale L. Tanga,b,n
aDivision of Vascular Surgery, Department of Surgery, University of Washington, Seattle, WA
bVA Puget Sound Health Care System, Surgical Services 112, 1660 S. Columbian Way, Seattle, WA 98108a r t i c l e i n f odx.doi.org/10.1053/j.semvascsurg.2015
967/$ - see front matter Published by E
creativecommons.org/licenses/by-nc-
responding author.
ail address: gtang@uw.edu (G.L. Tana b s t r a c t
Renal insufﬁciency is associated with an increased incidence of poor outcomes, including
cardiovascular events and death, in the general population. Renal dysfunction appears to
have a particularly negative impact in patients undergoing vascular surgery and endovas-
cular therapy. Although the exact mechanism is unknown, increased levels of inﬂamma-
tory and biochemical modulators associated with adverse cardiovascular outcomes, as well
as endothelial dysfunction, appear to play a role in the association between renal
insufﬁciency and adverse outcomes. Outcomes after the surgical and endovascular treat-
ment of abdominal aortic aneurysms, carotid disease, and peripheral arterial disease are all
negatively affected by renal insufﬁciency. Patients with renal dysfunction may warrant
intervention for the treatment of critical limb ischemia and symptomatic carotid stenosis,
given the comparatively worse outcomes associated with medical management. Open
repair of aortic aneurysms and carotid intervention for asymptomatic disease in patients
with severe renal dysfunction should be performed with signiﬁcant caution, as the risks of
repair may outweigh the beneﬁts in this population. Further study is needed to better
delineate the risks of medical management for these conditions in patients with coexisting
severe renal dysfunction. Lastly, current guidelines for the management of vascular
diseases, including objective performance goals for critical limb ischemia, are likely not
applicable in patients with severe renal insufﬁciency.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Renal insufﬁciency has been shown to be an independent
predictor of hospitalization, cardiovascular events, and death
[1]. Understanding the effect of renal insufﬁciency in vascular
surgery is critical, as renal dysfunction has been demon-
strated to impact negatively on outcomes in patients under-
going vascular interventions [2–5]. This article reviews
various aspects of the association between renal dysfunction
and adverse vascular surgery outcomes. Glomerular ﬁltration.01.006
lsevier Inc. This is an op
nd/4.0/).
g).rate (GFR) is introduced as the best available method of
measuring renal function. The importance of renal function
as a preoperative and postoperative variable on surgical
outcomes is then discussed. Potential explanations for the
relationship between renal insufﬁciency and poor outcomes
in vascular surgery are brieﬂy presented. The literature on the
effect of GFR on outcomes after vascular and endovascular
surgery for aortic aneurysms, carotid stenosis, and peripheral
vascular disease is then reviewed. Therefore, this article
provides practitioners with an overview of the additionalen access article under the CC BY-NC-ND license
S E M I N A R S I N V A S C U L A R S U R G E R Y 2 7 ( 2 0 1 4 ) 1 6 2 – 1 6 9 163risks imparted by renal insufﬁciency on various vascular
interventions. It remains difﬁcult to determine whether those
additional risks outweigh the beneﬁts of intervention in the
absence of better studies of the outcomes of medically
managed patients with vascular conditions. The limited life
expectancy of these patients should be taken into account for
any procedures being considered for prophylactic reasons.Table 1 – Stages of chronic kidney disease.
CKD
stage
Description GFR (mL/min/1.73
m2)
I Normal or mildly decreased
GFR
Z90
II Normal or mildly decreased
GFR
6089
III Moderately decreased GFR 3059
IV Severely decreased GFR 1529
V Severely decreased GFR o15
Abbreviations: CKD, chronic kidney disease; GFR, glomerular
ﬁltration rate.2. Renal dysfunction prevalence and deﬁnition
Renal insufﬁciency is prevalent in patients undergoing vas-
cular surgery and endovascular interventions. The preva-
lence of renal insufﬁciency, deﬁned as serum creatinine 42
mg/dL, in patients undergoing infrainguinal interventions for
peripheral vascular disease has been reported to be 420% in
a single-center study [6]. In a study of 48,000 patients in the
National Surgical Quality Improvement Program who under-
went repair of intact abdominal aortic aneurysms (AAAs), the
prevalence of stage III chronic kidney disease (CKD) was 30%,
while the prevalence of stage IV or V CKD was 7% [4]. A study
from the Veterans Affairs National Surgical Quality Improve-
ment Program of 420,000 patients who underwent carotid
endarterectomy demonstrated that 31% of patients had stage
III CKD, and 2% of patients had stage IV or V CKD [5]. Patients
with impaired renal function currently represent a signiﬁcant
proportion of patients undergoing vascular surgery interven-
tions. This proportion is likely to increase, given the increas-
ing prevalence of type II diabetes and an aging population,
emphasizing the importance of vascular surgeons and endo-
vascular therapists being familiar with the increased risks of
intervention in this population.
Historically, serum creatinine levels have been used to
measure renal function. However, the association between
serum creatinine and GFR is not linear, as GFR may decline to
half the normal level before serum creatinine reaches the
upper limit of normal [3,7]. As a result, serum creatinine is a
poor reﬂection of actual renal function. GFR is considered to
be the best available method of measuring renal function [8].
Initially, the Cockcroft-Gault equation was used to calculate
an estimated GFR (eGFR) [9]. However, the equation derived
from the Modiﬁcation of Diet in Renal Disease (MDRD) study:
eGFR ¼ 175  Serum Cr1.154 * age0.203 * 1.212 (if patient is
black) * 0.742 (if patient is female), has been shown to be more
accurate, and has supplanted the Cockcroft-Gault equation.
One limitation of the MDRD equation is that it underesti-
mates GFR at higher levels of renal function [10]. A revised
method of estimating GFR, the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation, was devel-
oped to addresses this issue [11]. Indeed, early studies
support that the CKD-EPI equation may be better than the
MDRD equation in estimating GFR in patients with normal
renal function [10,12].
The National Kidney Foundation Kidney Disease Outcomes
Quality Initiative guidelines utilize GFR to classify CKD into ﬁve
stages: stage I is GFR 490 mL/min/1.73 m2 (patients with no-
rmal renal function but genetic or structural predisposition to
renal disease or urine ﬁndings such as proteinuria or hema-
turia); stage II is GFR 60 to 90 mL/min/1.73 m2; stage III is GFR 30
to 60 mL/min/1.73 m2; stage IV is GFR 15 to 30 mL/min/1.73 m2;and stage V is GFRo15 mL/min/1.73 m2 [13]. This classiﬁcation
system is the most widely used and validated categorization of
CKD. In the vascular and endovascular surgery literature,
patients with stage I and II CKD have frequently been grouped
together and categorized as having “mild or no” disease;
patients with stage III CKD have been categorized as having
“moderate” disease; and patients with stage IV and V CKD have
been grouped together and categorized as having “severe”
disease (Table 1). This simpliﬁed classiﬁcation scheme and
terminology will be used hereafter to describe renal
dysfunction.3. Impact of GFR on morbidity and morality
In a seminal study, the eGFR of 1 million adults was
determined using the MDRD equation, and examined for its
association with adverse outcomes [1]. After adjusting for risk
factors, a history of cardiovascular disease, and proteinuria, a
reduced eGFR was linked with an increased risk of hospital-
ization, cardiovascular events, and death. In addition, the
study demonstrated that there was a graded association
between decreasing levels of eGFR and these outcomes. As
eGFR decreased to o60 mL/min/1.73 m2, the rate of hospital-
ization, cardiovascular events, and death increased. This
study corroborated the staging system utilizing GFR set forth
by the National Kidney Foundation, and emphasized the
importance of renal insufﬁciency, deﬁned as GFR o60 mL/
min/1.73 m2, as a marker for increased morbidity and mortal-
ity [14].4. Acute kidney injury after surgery and long-
term survival
The majority of literature on renal dysfunction and surgical
outcomes has focused on the effect of preoperative renal
insufﬁciency on postoperative outcomes. Few studies have
assessed the impact of acute kidney injury after surgery on
long-term outcomes. In an important study addressing this
issue, Bihorac et al [15] determined the relationship between
acute kidney injury and long-term survival in 410,000
patients who were admitted to a surgical intensive care unit
for at least 24 hours after major surgery. Acute kidney injury
was deﬁned by the RIFLE (risk, injury, failure, loss, and end-
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change in serum creatinine or GFR [16]. This study found
that acute kidney injury after surgery was associated with an
independent long-term risk of death. In addition, there
remained an increased risk of mortality in patients with
acute kidney injury, even when there had been complete
recovery of renal function by the time of hospital discharge.
The authors concluded that patients with acute kidney injury
merited close post-discharge follow-up due to their decreased
long-term survival.5. Potential explanations for association
between renal insufﬁciency and poor outcomes
There are several possible explanations for the relationship
between renal function and adverse events. First, renal
insufﬁciency has been shown to accelerate cardiovascular
calciﬁcation and atherosclerosis and alters vascular remodel-
ing [17–20]. Patients with kidney dysfunction have higher
levels of homocysteine and C-reactive protein, and lower
levels of apolipoprotein A1, which have been associated with
an increased risk for cardiovascular disease [21]. Increased
inﬂammation can also play a role, as elevated levels of
inﬂammatory biomarkers, including interleukin-6, tumor
necrosis factor, and C-reactive protein, have been found in
patients with renal insufﬁciency [22]. It is unclear whether
this reﬂects impaired renal clearance of inﬂammatory bio-
markers, or a causal role in acceleration of atherosclerosis
and therefore worse outcomes [3].
Another important observation in the study of renal insuf-
ﬁciency and cardiovascular events comes from Chong et al
[23]. In this study of patients with peripheral arterial disease,
linear regression was used to determine the relationship
between endothelial and renal dysfunction. Endothelial dys-
function was assessed by ﬂow-mediated vasodilation, and
renal dysfunction was measured by eGFR. This study found
that renal dysfunction had a stronger relationship with
endothelial dysfunction than hypertension, dyslipidemia,
and coronary artery disease. The authors concluded that
further investigation would be needed to evaluate whether
the prevention of worsening of renal dysfunction might pre-
empt further endothelial dysfunction, and thereby decrease
the associated risk of cardiovascular events. Although the
mechanism by which renal insufﬁciency portends worse
outcomes has yet to be elucidated, there is ample literature
from clinical studies, which will be discussed here, that
demonstrates that GFR is an independent and powerful risk
factor for poor outcomes in vascular patients.
Although the literature is not unanimous, there appears to
be a beneﬁt of statin therapy on renal-speciﬁc outcomes in
patients undergoing endovascular surgery. A single-center
study of 287 patients undergoing endovascular aneurysm
repair suggested that statin therapy may prevent acute
kidney injury [24,25]. It is possible that, through lowering
peripheral vascular resistance, improving endothelial dys-
function, and reducing inﬂammation, statins exert renal
protective effects and improve perioperative outcomes [26].
A single-center study of patients undergoing endovascular
aneurysm repair failed to show any beneﬁcial effect of statintherapy on postoperative estimated GFR or risk of GFR decline
[27]. However, given the improvement in survival with peri-
operative statin use in patients undergoing vascular surgery,
it is difﬁcult to argue that vascular patients should not be on
statin therapy [28,29].6. Aortic aneurysms
The impact of renal insufﬁciency on the treatment of aortic
aneurysms has been well described. Dr. Crawford’s experi-
ence with the management of 41,500 thoracoabdominal
aortic aneurysms is a seminal study in the management of
this complex disease process [30]. This study is also note-
worthy for its insightful examination of the role of preoper-
ative kidney dysfunction on 30-day mortality, and the effect
of postoperative renal complications on long-term survival.
Despite the infrequent inclusion of patients with preopera-
tive renal dysfunction (13% of the included patients), renal
function still had a profound effect on postoperative out-
comes. Higher preoperative renal creatinine predicted 30-day
mortality by multivariate analysis, with patients with preop-
erative renal insufﬁciency experiencing a 30-day mortality of
13% compared with 7% (P ¼ .0072) in those without preoper-
ative dysfunction. This study also examined the impact of
postoperative renal complications on long-term survival, and
found that patients who sustained postoperative renal com-
plications had a 5-year survival of 30% compared to 66% (P o
.0001) for those patients who did not. Of note, kidney failure,
deﬁned as postoperative creatinine level 43 mg/dL or need
for dialysis, occurred in 18% of patients in this single-center
of excellence experience. Although this study did not utilize
GFR as a measurement of renal function, the results high-
lighted the importance of renal insufﬁciency on surgical
outcomes after aneurysm repair for future investigations.
Azizzadeh et al [31] continued this work by investigating
whether GFR was superior to serum creatinine in predicting
outcomes after thoracic aortic aneurysm repair. The authors
analyzed 41,100 thoracoabdominal aortic aneurysms and
descending thoracic aortic aneurysms repaired between
1991 and 2004. GFR was estimated using the Cockcroft-Gault
equation. Although both serum creatinine and eGFR pre-
dicted 30-day mortality, the latter was a much more powerful
predictor of mortality. For example, patients with an eGFR
490 mL/min/1.73 m2 had a 30-day mortality of 5%, compared
to a 30-day mortality of 430% (P ¼ .0001) in patients with an
eGFR o30 mL/min/1.73 m2. The authors concluded that GFR
was superior to serum creatinine in identifying patients with
subclinical renal disease who would not otherwise be classi-
ﬁed as having renal insufﬁciency if serum creatinine were
utilized to estimate renal function. The recommendation
from these results was that elective repair of aneurysms
involving the thoracic aorta should be undertaken with
considerable caution in patients with severe renal insufﬁ-
ciency, and that these patients should be considered at high
risk for surgical repair.
Data from the National Surgical Quality Improvement
Program was used to evaluate the effect of CKD stage on
30-day mortality in 48,000 patients after endovascular
(EVAR) and open repair of AAA [4]. Patients were assigned
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Kidney Disease Outcomes Quality Initiative guidelines based
on their eGFR calculated by the MDRD equation. Propensity
score analysis was then used to match cohorts of patients
with mild versus moderate and mild versus severe CKD.
Patients with moderate versus mild CKD who underwent
EVAR had higher rates of 30-day mortality (3% v 2%; P ¼ .013)
and complications (14% v 8%; P o .0001). Similarly, patients
with moderate CKD who underwent open aneurysm repair
had higher rates of 30-day mortality (8% v 3%; P o .0001) and
complications (32% v 25%; P ¼ .001). The differences in
mortality and morbidity were even more dramatic when
patients with severe CKD were compared with those with
mild disease. Patients who underwent EVAR had increased
30-day mortality (6% v 3%; P ¼ .0081) and complications (19%
v 11%; P o .0001). Patients with severe CKD who underwent
open repair of AAA had a 30-day mortality rate of 10% and a
40% rate of any complication. The suggestion from this study
was that the diameter threshold for repair of AAA in patients
with renal insufﬁciency be raised to 46.0 cm [4]. In addition,
the authors concluded that the morbidity and mortality of
open AAA repair in patients with severe CKD were signiﬁ-
cant enough that elective repair in such patients could
not be recommended, except in “extenuating clinical
circumstances.”
Similar to the effect of postoperative renal complications
on long-term outcomes after thoracoabdominal aortic aneur-
ysm repair, the impact of postoperative acute kidney injury
on 5-year survival after open AAA repair has also been
demonstrated. A single-center’s experience with open repair
of infrarenal, pararenal, and extent IV thoracoabdominal
aortic aneurysms was examined in order to determine pre-
dictors of decreased survival [32]. The impact of postoperative
renal complication on long-term survival was one of the key
ﬁndings of this study. Acute kidney injury after surgery
was identiﬁed if the patient’s postoperative renal function
declined by at least one stage of CKD compared to their
preoperative renal function. In this study of 4400 open AAA
repairs, the majority of which involved suprarenal and
supraceliac clamps, 19% of patients had postoperative
renal complications. Patients who had postoperative renal
complications had a 5-year survival of 40% compared to 70%
(P ¼ .004) for patients who did not have postoperative
renal complications. The development of techniques to
decrease the incidence of postoperative renal complications
in patients undergoing repair of complex aortic aneurysms
was highlighted as an important area of future investigation.
The emergence, and growing dominance, of endovascular
therapy in the management of aortic aneurysms has raised
questions about the effect of this treatment modality on renal
function. The Dutch Randomized Endovascular Aneurysm
Management (DREAM) trial investigators performed a post-
hoc analysis evaluating the impact of open and endovascular
repair of infrarenal AAA on renal function [33]. After 5 years
of follow-up, the mean eGFR was not signiﬁcantly different
between the open and endovascular repair groups (76 v 75
mL/min/1.73 m2), and concluded that neither management
option accelerated the loss of renal function. It is important
to note thato10% of the patients included in the DREAM trial
had renal disease. As preoperative renal insufﬁciency is oneof the most powerful predictors of postoperative acute kidney
injury, these ﬁndings are not necessarily applicable to many
of the patients evaluated outside of this clinical trial [30].
While endovascular repair of infrarenal AAA appears to
confer no increased risk of renal dysfunction, the repair of
aortic aneurysms involving the renal arteries deserves closer
and separate scrutiny. There are relatively few data on renal
function after the endovascular repair of juxtarenal and
pararenal aortic aneurysms. Haulon et al [34] reported on
their experience with the endovascular repair of 80 juxtare-
nal, pararenal, and thoracoabdominal aortic aneurysms. In
this multicenter experience, 11% of patients sustained post-
operative acute kidney injury, deﬁned as a decrease in eGFR
of at least 30%. One patient required permanent dialysis. The
recent publication of outcomes in patients with juxtarenal
aortic aneurysms treated with a fenestrated endovascular
graft offers additional insight [35]. In this multicenter study,
57 patients with juxtarenal AAAs underwent fenestrated
EVAR. Although the study did not indicate how it deﬁned
preoperative renal insufﬁciency or postoperative renal com-
plication, approximately 25% of the patients were reported to
have preoperative renal insufﬁciency, with only 7% of
patients being reported to have sustained perioperative acute
kidney injury. Compared with rates of acute kidney injury
that are approximately Z20% after open repair of complex
AAAs [32,36], these results suggest that the endovascular
repair of complex aortic aneurysms may be particularly
beneﬁcial in decreasing postoperative renal complications
and the associated decreased long-term survival [4,32]. None-
theless, enthusiasm for the endovascular approach needs to
be tempered until data on the long-term risk of renal
occlusion and renal stent stenosis with this approach
becomes available, and further studies show whether similar
results can be achieved outside of centers of excellence with
signiﬁcant experience in fenestrated endografts [37].7. Carotid disease
Outcomes after vascular and endovascular surgery for carotid
stenosis are increasingly scrutinized. Identifying preoperative
factors that predict worse outcomes after carotid interven-
tions are particularly helpful and timely. Renal insufﬁciency
has been identiﬁed as a risk factor for increased morbidity
and mortality in patients undergoing carotid procedures. In a
study utilizing the Veteran Affairs National Surgical Quality
Improvement Program dataset, the effect of eGFR (calculated
by the MDRD equation) on outcomes after carotid endarter-
ectomy in 20,000 patients was evaluated [5]. Patients were
divided into three groups based on eGFR, mild renal dysfunc-
tion, moderate renal dysfunction, and severe renal dysfunc-
tion. Outcomes included 30-day mortality and major
complications, including neurologic, cardiac, pulmonary,
and infectious. The study found that patients with moderate
renal insufﬁciency were at increased risk of cardiac and
pulmonary complications, and that patients with severe
renal insufﬁciency were at increased risk of 30-day mortality,
compared to patients with normal or mildly reduced renal
function. The conclusion from the study was that renal
insufﬁciency is an important and independent risk factor of
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mortality rate of 3.1% in patients with severe renal dysfunc-
tion was particularly noteworthy as the Asymptomatic Car-
otid Atherosclerosis Study demonstrated that patients with
asymptomatic carotid artery stenosis will have a reduced
5-year risk of ipsilateral stroke if carotid endarterectomy is
performed with o3% perioperative morbidity and mortality
rate [38]. Future studies of the natural history, including the
risk of stroke and death, of medically managed patients with
renal insufﬁciency and asymptomatic moderate- and high-
grade carotid stenosis are needed to determine whether the
stroke risk reduction achieved by carotid intervention out-
weighs the increased risk in this patient group.
Given the improved outcomes with the medical manage-
ment of asymptomatic carotid disease, it has been become
increasingly important to identify patients who will and will
not beneﬁt from carotid revascularization. The Vascular
Study Group of New England examined factors associated
with 5-year survival after carotid endarterectomy in patients
with asymptomatic internal carotid artery stenosis [39].
Dialysis dependence and GFR o60 mL/min/1.73 m2 were
two of several risk factors identiﬁed by multivariate analysis
as predictive of decreased survival at 5 years. eGFR o60 mL/
min/1.73 m2 was a minor risk factor, while dialysis depend-
ence was a major risk factor. Patients identiﬁed as high-risk
had a 51% 5-year survival, compared to an 80% 5-year
survival for patients identiﬁed as medium and low risk. Of
note, only 5% of the patients included in the study were high
risk. The authors concluded that the risk factors and pre-
diction model derived from this analysis would be helpful in
determining who would survive long-term after carotid
endarterectomy and therefore beneﬁt from the procedure.
Although carotid angioplasty and stenting has a different
risk proﬁle than carotid endarterectomy, including a lower
risk of myocardial infarction and a higher risk of stroke,
preoperative renal insufﬁciency remains a predictor of poor
outcomes in patients undergoing carotid stenting [40]. Pro-
tack et al [41] evaluated the effect of renal dysfunction (as
determined by eGFR calculated by the MDRD equation) on
carotid angioplasty and stenting at a single-center during a
10-year period. Similar to previous studies, patients were
divided into groups with normal renal function or mild renal
dysfunction, moderate renal dysfunction, and severe renal
dysfunction. Patients with severe renal dysfunction com-
pared with patients with normal renal function and moderate
renal dysfunction had worse 30-day mortality (15% v 1% and
3%; P ¼ .02) and stroke (23% v 4% and 3%; P ¼ .01) rates.
Patients with moderate and severe renal insufﬁciency had 5-
year survival rates o60%, compared to a 5-year survival rate
of 87% (P ¼ .003) for patients with normal renal function.
These results suggest that severe renal dysfunction also has
an adverse impact on perioperative outcomes after carotid
angioplasty and stenting.
Although patients with renal insufﬁciency have worse
outcomes after carotid interventions, it appears that patients
with kidney dysfunction and symptomatic high-grade steno-
sis may fare even worse without intervention, and, therefore,
may still beneﬁt from revascularization [42]. In a re-analysis
of the data from the North American Symptomatic Carotid
Endarterectomy Trial, patients with symptomatic stenosiswith stage III CKD (n ¼ 524) were compared with patients
with stage I and II CKD (n ¼ 966). Patients with renal
insufﬁciency who received nonoperative management had a
higher ipsilateral stroke rate at 2 years (32%) compared to
patients who received operative management (19%) (P ¼ .042).
Carotid endarterectomy signiﬁcantly reduced the stroke risk
with a number needed to treat of 4 for patients with stage III
CKD, compared to a number needed to treat of 10 for patients
with preserved renal function. The conclusion of this post-
hoc analysis was that patients with stage III CKD and
symptomatic high-grade carotid stenosis beneﬁted from
carotid endarterectomy [42]. Future studies are required to
determine whether this provocative ﬁnding based on post-
hoc analysis is borne out prospectively.8. Peripheral arterial disease
Many patients with cardiovascular disease have both periph-
eral arterial disease and renal insufﬁciency, and several
studies have examined the relationship between eGFR and
outcomes after infrainguinal revascularization [3,43]. In a
single-center study, 456 patients who underwent primary
lower-extremity bypass surgery during a 10-year period at a
single institution were stratiﬁed by eGFR, as calculated by the
MDRD equation, into stages of CKD. Patients with severe
renal insufﬁciency had a higher rate of the combined end-
point of postoperative myocardial infarction and mortality.
Long-term survival also differed by CKD stage. Due to sim-
ilarities in hazard ratios, patients with stages I, II, and III CKD
(eGFR 430 mL/min/1.73 m2) were compared to patients with
stages IV and V CKD (eGFR o30 mL/min/1.73 m2). The 5-year
survival for patients with an eGFR 430 mL/min/1.73 m2 was
53% compared to 11% (P o .0001) for patients with an eGFR
o30 mL/min/1.73 m2. Employing the same groups for analy-
sis, the authors found that the 5-year amputation-free sur-
vival for patients with an eGFR430 mL/min/1.73 m2 was 49%
versus 8% (P o .0001) for patients with an eGFR o30 mL/min/
1.73 m2. These ﬁndings suggest that an eGFR o30 mL/min/
1.73 m2 is a powerful predictor of perioperative myocardial
infarction and death, as well as long-term mortality and
amputation in patients undergoing infrainguinal bypass sur-
gery for peripheral vascular disease [3].
Renal insufﬁciency appears to impart a similar adverse
effect in percutaneous interventions for infrainguinal periph-
eral arterial disease. The impact of CKD on perioperative and
late outcomes was examined in a retrospective study of 879
patients who underwent endovascular therapy for lower-
extremity peripheral arterial disease at a single institution
during an 8-year period; 14% of these patients had severe
CKD [43]. Similar to the ﬁndings from open revascularization,
an eGFR o30 mL/min/1.73 m2 predicted worse outcomes.
Five-year survival in patients undergoing percutaneous
peripheral vascular interventions was 24% in patients with
eGFR o30 mL/min/1.73 m2 versus 69% in patients without
severe CKD (P o .05). Freedom from amputation at 2-years
was 80% in the eGFRo30 mL/min/1.73 m2 group compared to
97% in the other group (Po .001). There were no amputations
observed after 2 years. Of note, approximately 30% of the
patients in this study had claudication and, therefore, less
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stage V CKD are not included in the objective performance
goals of critical limb ischemia, the ﬁnding that patients with
an estimated GFR o30 mL/min/1.73 m2 had a 1-year survival
of 69% is signiﬁcant, especially in the context of the objective
performance goal of 80% 1-year survival [44]. Objective
performance goals for critical limb ischemia require modiﬁ-
cation to reﬂect the poorer outcomes of patients with stage IV
and stage V CKD.
These studies highlight the adverse effect of severe CKD
on outcomes after surgical and endovascular interventions
in patients with peripheral arterial disease. However, other
treatment strategies may be associated with even worse
outcomes than surgery or endovascular therapy in patients
with severe CKD and peripheral vascular disease. Ortmann
et al [45] examined the potential survival beneﬁt of revascu-
larization versus medical therapy in patients with critical
limb ischemia and various stages of renal function. In this
study of almost 400 consecutive patients with critical limb
ischemia, patients were classiﬁed as receiving either revas-
cularization or medical therapy based on the primary ther-
apeutic decision made at the patient’s initial presentation.
Approximately one-quarter of patients were treated with
medical therapy. Of the roughly three-quarters of patients
who underwent revascularization, approximately 70% were
treated with endovascular therapy, and 30% were managed
with bypass surgery. This study is limited by patient-
selection bias, as toe pressure and transcutaneous oxygen
pressure were lower in the medical therapy cohort, suggest-
ing more advanced atherosclerotic disease. Other risk fac-
tors were similar between the two groups. After adjusting for
risk factors, primary revascularization resulted in improved
survival compared to primary medical therapy in all patients
included in the study. In particular, patients with severe
renal insufﬁciency experienced a survival beneﬁt with pri-
mary revascularization versus medical therapy. Of note,
limb salvage was not improved by revascularization in
patients with severe CKD. One-year mortality in all patients
in this cohort study was 30%, with a 1-year mortality of 49%
in patients with severe renal dysfunction, highlighting the
challenges encountered when treating patients with periph-
eral arterial disease and renal insufﬁciency. Nevertheless,
the authors concluded that surgical and endovascular treat-
ment may still be warranted in patients with critical limb
ischemia and severe renal dysfunction, as the alternative of
withholding revascularization might result in even worse
outcomes.
In a complementary study, Barshes et al [46] utilized a
probabilistic Markov model to simulate the outcomes of
various treatment strategies in patients with nonhealing foot
wounds and end-stage renal disease. Comparing wound care
alone, primary amputation, and various revascularization
strategies, this study demonstrated that either local wound
care or endovascular therapy might be more cost-effective
than primary amputation. By avoiding the perioperative risks,
deterioration in quality of life, and increased costs of long-
term assisted-living associated with amputation, local wound
care may be a particularly beneﬁcial strategy in patients who
do not have options of revascularization. The authors empha-
sized that further studies will be needed to delineate thefunctional outcomes and wound healing rates of patients
with end-stage renal disease and nonhealing foot wounds.9. Conclusions
Renal function, as measured by GFR, should feature prom-
inently in the decision making of vascular surgeons when
evaluating patients with aortic aneurysms, carotid stenosis,
and peripheral arterial disease for possible intervention, as
there is a large body of evidence supporting the association
between renal dysfunction and adverse postoperative out-
comes. As the current literature is mainly comprised of
operative results from single-center studies, future investi-
gations are needed to better determine the outcomes after
both nonoperative and operative management of vascular
disease in patients with moderate or severe CKD.
Moderate CKD results in signiﬁcant increased morbidity
and mortality after open repair of AAAs. As such, it is
reasonable to increase the diameter threshold for repair in
these patients to 6 cm. In patients with severe renal
dysfunction, deﬁned as an eGFR o30 mL/min/1.73 m2, open
repair of AAAs should probably not be undertaken, although
EVAR may be considered for those patients with an AAA 46
cm. Endovascular repair of complex aortic aneurysm may
result in improved renal outcomes compared to open repair.
Neither carotid endarterectomy nor angioplasty and stent-
ing appears to be warranted in patients with severe renal
dysfunction and asymptomatic carotid stenosis, as the 30-
day mortality rates appear to be higher than those deemed
acceptable in the repair of asymptomatic disease. Patients
with renal insufﬁciency and symptomatic high-grade carotid
stenosis have worse surgical outcomes than patients without
renal insufﬁciency; however, medical therapy may confer
even worse outcomes than operative intervention. Recom-
mendations for the management of peripheral arterial dis-
ease in patients with severe renal dysfunction follow a
similar algorithm. While outcomes in patients with severe
renal dysfunction are worse than in patients with mild or
moderate renal dysfunction, revascularization appears to
result in improved outcomes compared to medical therapy
or amputation. Strategies to ameliorate the deleterious
effects of renal dysfunction on vascular surgery outcomes
are needed, and should be a focus of future investigations.Acknowledgements
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